论文部分内容阅读
目的观察米非司酮联合甲氨蝶呤治疗宫外孕的临床疗效。方法选取2013年1月~2016年3月医院科室收治的82例宫外孕孕妇,随机分为观察组和对照组各41例。对照组患者只给予甲氨蝶呤治疗,观察组在对照组治疗基础上联合口服米非司酮。结果观察组血β-h CG水平为(1256.8±42.5)U/ml,明显低于对照组的(1911.6±54.1)U/ml;观察组的腹痛消失时间和包块消失时间也均少于对照组,以上各指标间比较差异均有统计学意义(均P<0.05)。观察组治愈率高达92.7%,显著高于对照组的73.2%,差异有统计学意义(P<0.05)。结论米非司酮联合甲氨蝶呤治疗宫外孕患者,可以降低血β-h CG水平,改善临床症状,提高疗效。
Objective To observe the clinical efficacy of mifepristone combined with methotrexate in the treatment of ectopic pregnancy. Methods 82 cases of ectopic pregnancy admitted to hospital department from January 2013 to March 2016 were randomly divided into observation group and control group, 41 cases each. Patients in the control group were treated with methotrexate only. The observation group was given oral mifepristone on the basis of the control group. Results The level of β-h CG in the observation group was (1256.8 ± 42.5) U / ml, which was significantly lower than that in the control group (1911.6 ± 54.1) U / ml. The disappearance time and disappearance time of abdominal pain in the observation group were also less than those in the control group Group, the above indicators were significantly different between the two groups (all P <0.05). The cure rate of the observation group was as high as 92.7%, which was significantly higher than that of the control group (73.2%), the difference was statistically significant (P <0.05). Conclusion Mifepristone combined with methotrexate in patients with ectopic pregnancy, can reduce the level of blood β-h CG, improve clinical symptoms and improve efficacy.